BG-12 In MS, Two Long-Acting Hemophilia Drugs Key To Scangos’ Revitalized Biogen Idec

An R&D overhaul trimmed 17 candidates from the pipeline, but as several late-stage programs near potential approval, the biotech says it will resume focus on discovery and validation of new targets.